Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Short Interest Update

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLCGet Rating) was the target of a large decline in short interest in May. As of May 15th, there was short interest totalling 2,600 shares, a decline of 69.8% from the April 30th total of 8,600 shares. Based on an average trading volume of 220,000 shares, the days-to-cover ratio is currently 0.0 days.

Oncotelic Therapeutics stock traded up $0.00 during trading hours on Friday, hitting $0.23. 134,048 shares of the stock traded hands, compared to its average volume of 142,499. The firm’s 50-day moving average price is $0.22 and its two-hundred day moving average price is $0.19. The company has a market cap of $87.79 million, a PE ratio of -5.75 and a beta of 0.75. Oncotelic Therapeutics has a one year low of $0.08 and a one year high of $0.30.

Oncotelic Therapeutics Company Profile (Get Rating)

Oncotelic Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.

Featured Stories

Receive News & Ratings for Oncotelic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncotelic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.